DNER and cancer: To evaluate efficacy of BET bromodomain/HER2 kinase inhibition on cancer cells in the presence of fibroblast-secreted factors, we treated cells with 1 μM JQ1 plus either 300 nM or 1 μM lapatinib and measured the reduction in viable cells (Fig. 4B).